These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 11848529

  • 1. Serum soluble Fas level for detection and staging of prostate cancer.
    Furuya Y, Fuse H, Masai M.
    Anticancer Res; 2001; 21(5):3595-8. PubMed ID: 11848529
    [Abstract] [Full Text] [Related]

  • 2. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
    Trojan L, Bode C, Weiss C, Mayer D, Grobholz R, Alken P, Michel MS.
    Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
    [Abstract] [Full Text] [Related]

  • 3. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
    Hammarsten J, Högstedt B.
    Scand J Urol Nephrol; 2002 Feb; 36(5):330-8. PubMed ID: 12487736
    [Abstract] [Full Text] [Related]

  • 4. Hormonal predictors of prostate cancer.
    Sofikerim M, Eskicorapci S, Oruç O, Ozen H.
    Urol Int; 2007 Feb; 79(1):13-8. PubMed ID: 17627161
    [Abstract] [Full Text] [Related]

  • 5. Clinical usefulness of serum antip53 antibodies for prostate cancer detection: a comparative study with prostate specific antigen parameters.
    Suzuki H, Akakura K, Igarashi T, Ueda T, Ito H, Watanabe M, Nomura F, Ochiai T, Shimada H.
    J Urol; 2004 Jan; 171(1):182-6. PubMed ID: 14665872
    [Abstract] [Full Text] [Related]

  • 6. [Value of prostate specific antigen in early diagnosis of prostatic cancer].
    Xiao LP, Bi XJ, Li YN, Chen XQ, Zhang XF, Yu XP, Liu G, Yang MC, Song Z.
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Jan; 27(1):107-8, 112. PubMed ID: 17259162
    [Abstract] [Full Text] [Related]

  • 7. Prognostic significance of soluble Fas in the serum of patients with bladder cancer.
    Mizutani Y, Yoshida O, Bonavida B.
    J Urol; 1998 Aug; 160(2):571-6. PubMed ID: 9679930
    [Abstract] [Full Text] [Related]

  • 8. Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer.
    Lehrer S, Diamond EJ, Stagger S, Stone NN, Stock RG.
    Br J Cancer; 2002 Sep 23; 87(7):726-8. PubMed ID: 12232754
    [Abstract] [Full Text] [Related]

  • 9. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
    Capitanio U, Scattoni V, Freschi M, Briganti A, Salonia A, Gallina A, Colombo R, Karakiewicz PI, Rigatti P, Montorsi F.
    Eur Urol; 2008 Jul 23; 54(1):118-25. PubMed ID: 18314255
    [Abstract] [Full Text] [Related]

  • 10. Contrast-enhanced gray-scale transrectal ultrasound-guided prostate biopsy in men with elevated serum prostate-specific antigen levels.
    Yang JC, Tang J, Li J, Luo Y, Li Y, Shi H.
    Acad Radiol; 2008 Oct 23; 15(10):1291-7. PubMed ID: 18790401
    [Abstract] [Full Text] [Related]

  • 11. Prevalence of prostate cancer at different levels of serum prostate-specific antigen (PSA) and different free: total PSA ratios in a consecutive series of men referred for prostate biopsies.
    Rydén L, Egevad L, Ekman P, Hellström M.
    Scand J Urol Nephrol; 2007 Oct 23; 41(4):302-7. PubMed ID: 17763221
    [Abstract] [Full Text] [Related]

  • 12. Insulin-like growth factor 1, chromogranin A and prostate specific antigen serum levels in prostate cancer patients and controls.
    Marszalek M, Wachter J, Ponholzer A, Leitha T, Rauchenwald M, Madersbacher S.
    Eur Urol; 2005 Jul 23; 48(1):34-9. PubMed ID: 15967249
    [Abstract] [Full Text] [Related]

  • 13. Serum soluble fas level as a prognostic factor in patients with gynecological malignancies.
    Konno R, Takano T, Sato S, Yajima A.
    Clin Cancer Res; 2000 Sep 23; 6(9):3576-80. PubMed ID: 10999747
    [Abstract] [Full Text] [Related]

  • 14. The chromogranin-A (CgA) in prostate cancer.
    Ranno S, Motta M, Rampello E, Risino C, Bennati E, Malaguarnera M.
    Arch Gerontol Geriatr; 2006 Sep 23; 43(1):117-26. PubMed ID: 16280180
    [Abstract] [Full Text] [Related]

  • 15. Volume-based evaluation of serum assays for new prostate-specific antigen isoforms in the detection of prostate cancer.
    Naya Y, Fritsche HA, Bhadkamkar VA, Mikolajczyk SD, Rittenhouse HG, Babaian RJ.
    Urology; 2004 Mar 23; 63(3):492-8. PubMed ID: 15028444
    [Abstract] [Full Text] [Related]

  • 16. Role of cell-free plasma DNA as a diagnostic marker for prostate cancer.
    Allen D, Butt A, Cahill D, Wheeler M, Popert R, Swaminathan R.
    Ann N Y Acad Sci; 2004 Jun 23; 1022():76-80. PubMed ID: 15251943
    [Abstract] [Full Text] [Related]

  • 17. Diagnostic validity of macrophage migration inhibitory factor in serum of patients with prostate cancer: a re-evaluation.
    Michael A, Stephan C, Kristiansen G, Burckhardt M, Loening SA, Schnorr D, Jung K.
    Prostate; 2005 Jan 01; 62(1):34-9. PubMed ID: 15389818
    [Abstract] [Full Text] [Related]

  • 18. Circulating soluble Fas concentration in breast cancer patients.
    Ueno T, Toi M, Tominaga T.
    Clin Cancer Res; 1999 Nov 01; 5(11):3529-33. PubMed ID: 10589768
    [Abstract] [Full Text] [Related]

  • 19. The value of prostatic acid phosphatase and prostate specific antigen as serum markers in carcinoma of the prostate.
    Akdaş A, Simşek F, Ilker Y, Türkeri L, Ercan H.
    Int Urol Nephrol; 1993 Nov 01; 25(3):271-8. PubMed ID: 7693607
    [Abstract] [Full Text] [Related]

  • 20. Frequency of PSA-mRNA-bearing cells in the peripheral blood of patients after prostate biopsy.
    Hara N, Kasahara T, Kawasaki T, Bilim V, Tomita Y, Obara K, Takahashi K.
    Br J Cancer; 2001 Aug 17; 85(4):557-62. PubMed ID: 11506496
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.